Menu
Recruiting NCT06065228

Therapeutic Endpoint in Pediatric IBD Conditions

Observational Inflammatory Bowel Diseases Colitis, Ulcerative Crohn Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AlgometRx Nociometer.
Who it may be relevant to
Registry conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease. Basic parameters: 6 years — 21 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Development of a Therapeutic Endpoint in Pediatric IBD Conditions

Overview

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.

Interventions

  • Device AlgometRx Nociometer
    Physiologic characterization of disease activity

Primary outcome measures

  • The primary objective of this study is the measurement of the nociceptive index for clinical output. [Time frame: 1 Year]
Secondary outcome measures (1)
  • The secondary objective of this study is the characterization of the nociceptive index in IBD populations in response to standard of care interventions. [Time frame: 1 Year]

Eligibility criteria

Inclusion criteria

  • Male or female ≥ 6 years of age at screening.
  • Documentation of an IBD diagnosis as evidenced by history

Exclusion criteria

  • Documented history of eye disease precluding pupillometry
  • Patients who are unwilling or unable to participate due to developmental delays or ongoing psychological diagnoses.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Children's National Health System — Washington D.C.

Identifiers

NCT: NCT06065228 · STUDY00000658

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗